In this first-of-its-kind book, Crosstree profiles over 50 of the most innovative companies and thought leaders forging the future of Pharma Development. Each innovator profiled was carefully selected by a group of six independent industry experts. Companies are organized using Crosstree’s easily understandable and concise taxonomy to identify company groupings, sectors, and market trends at a granular level, using bottom-up data and decades of industry expertise. Learn more about Crosstree.
The book features in-depth, bottom-up analysis from Crosstree advisors and independent industry experts. Read the press release.
Anyone looking to discover the most innovative growth opportunities, partnerships, and investments in the clinical development space, including:
Crosstree’s expansive industry knowledge allowed us to focus on the most inspiring group of innovators and disruptors and provide in-depth profiles of each one”
Crosstree has taken the liberty to establish a more formalized approach to defining the Pharma Services industry by creating what we believe is an easily understandable and concise taxonomy from which we can better identify company groupings, sectors, and market trends at a more granular level.
The global availability of a vast array of cost-effective services from drug discovery to post-marketing surveillance has allowed for the increase in near-virtual development of drug and device candidates. This has allowed midsize and small-scale organizations to direct otherwise scarce investment capital directly into expert-driven outsourced services rather than the creation of costly, redundant, and often less effective internal development efforts.
The increase in the number of sophisticated new medicines associated with precision and specialty medicines, such as human and tumor genetics, is helping to drive the uptake of large-scale laboratory services in the development market. Additionally, the need for adherence to international regulatory standards is providing new opportunities for interoperability and automation of laboratory processes through innovative technologies.
Over the past decade, novel technologies have allowed for the efficient and cost-effective development of precision and specialty medicines. The drug and device development space is poised to make further profound leaps in productivity, cost reduction, and pace of innovation as it continues to embrace new technologies and methodologies, exploiting them to their fullest potential.